Genmab A/S
CSE:GMAB
Genmab A/S
CSE:GMAB
Price:
1 957.5 DKK
0.05%
Market Closed
Updated:
May 1, 2024
Genmab A/S
Cash from Operating Activities
|
Genmab A/S
Cash from Operating Activities Peer Comparison
Comparables:
ZEAL
ASND
B
BAVA
BIOPOR
SANION
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Operating Activities
kr7.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Operating Activities
-kr425.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-10%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Operating Activities
-€467.4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Operating Activities
kr1.1B
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
22%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Operating Activities
-kr55.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
Saniona AB
STO:SANION
|
Cash from Operating Activities
-kr85.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
See Also
What is Genmab A/S's Cash from Operating Activities?
Cash from Operating Activities
7.4B
DKK
7.4B
DKK
Based on the financial report for Dec 31, 2023, Genmab A/S's Cash from Operating Activities amounts to 7.4B DKK.
What is Genmab A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
49%
49%
Over the last year, the Cash from Operating Activities growth was 89%. The average annual Cash from Operating Activities growth rates for Genmab A/S have been 5% over the past three years , 49% over the past five years .
You don't have any saved screeners yet
